ClinicalTrials.gov
public full text
Public Domain
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine#980698
- Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder#883539
- Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus#894436
- A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers#917698
- Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.#877422
Record · ID 1031114
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive